May 30, 2017 09:38 AM EDT
Pharma

Sanofi beefs up can­cer drug pipeline, pay­ing cash hun­gry Im­muno­Gen $30M for full rights to on­col­o­gy port­fo­lio

John Carroll

Editor & Founder

Sanofi $SNY is once again re­jig­ging its part­ner­ship with Im­muno­Gen $IMGN. But two years af­ter punt­ing a can­cer drug as the phar­ma gi­ant over­hauled its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times